Suppr超能文献

糖尿病是否是肿瘤患者中心静脉置管相关血流感染的危险因素?

Is diabetes a risk factor for central venous access port-related bloodstream infection in oncological patients?

机构信息

INSERM Unit 1060/INRA 1235, University of Lyon, Lyon, France.

出版信息

Eur J Clin Microbiol Infect Dis. 2013 Jan;32(1):133-8. doi: 10.1007/s10096-012-1728-1. Epub 2012 Aug 22.

Abstract

It was a dogma that patients with diabetes mellitus (DM) are at increased risk of infection or death associated with an infection. However, in cancer patients, this has not been well investigated. The aim was to investigate whether diabetic patients with cancer are at high risk of central venous access port (CVAP)-related bloodstream infection (BSI), and to analyse mortality after CVAP-BSI. A total of 17 patients with type 1 DM (T1DM), 66 with type 2 DM (T2DM) and 307 non-diabetic patients were included. Each patient was followed up until the first late CVAP-BSI or for a maximum for 1 year in the absence of a CVAP-BSI. Fifty-three CVAP-BSIs occurred in 66,528 catheter-days. The cumulative incidence of CVAP-BSI was not higher in T1DM (5.9 %; p = 0.17) and T2DM (19.7 %; p = 0.70) compared with the non-diabetic patients (12.7 %). However, in patients with CVAP-BSI, the 1-month crude mortality rate was higher in DM patients (42.9 % vs. 15.4 %; p = 0.04), whereas the mortality in patients without CVAP-BSI was similar in both groups of patients (19.8 % vs. 17.1 %; p = 0.58). Of the 12 deaths that occurred within 1 month of CVAP-BSI, 16.66 % was attributable to CVAP-BSI. The predictive factor of 1-month mortality was DM (p = 0.04). Parenteral nutrition (PN) was independently associated with CVAP-BSI in diabetic patients (p = 0.001). In this study, diabetes did not increase the risk of CVAP-BSI, but mortality was higher in diabetic patients who had a CVAP-BSI. This suggests, in addition to medical treatment, CVAP should be withdrawn after infection onset.

摘要

有一种观点认为,糖尿病(DM)患者发生感染或感染相关死亡的风险增加。然而,在癌症患者中,这一点尚未得到充分研究。本研究旨在探讨癌症合并糖尿病患者是否存在中心静脉置管相关血流感染(CVAP-BSI)的高风险,并分析 CVAP-BSI 后的死亡率。共纳入 17 例 1 型糖尿病(T1DM)患者、66 例 2 型糖尿病(T2DM)患者和 307 例非糖尿病患者。每位患者在随访期间直至首次发生迟发性 CVAP-BSI 或在无 CVAP-BSI 的情况下随访 1 年。在 66528 天的导管使用时间中,共发生 53 例 CVAP-BSI。T1DM(5.9%;p=0.17)和 T2DM(19.7%;p=0.70)患者的 CVAP-BSI 累积发生率并不高于非糖尿病患者(12.7%)。然而,在发生 CVAP-BSI 的患者中,DM 患者的 1 个月粗死亡率更高(42.9%比 15.4%;p=0.04),而在无 CVAP-BSI 的患者中,两组患者的死亡率相似(19.8%比 17.1%;p=0.58)。在 CVAP-BSI 后 1 个月内发生的 12 例死亡中,有 16.66%归因于 CVAP-BSI。1 个月死亡率的预测因素为糖尿病(p=0.04)。糖尿病患者中,肠外营养(PN)与 CVAP-BSI 独立相关(p=0.001)。在本研究中,糖尿病并未增加 CVAP-BSI 的风险,但发生 CVAP-BSI 的糖尿病患者的死亡率更高。这表明,除了医疗治疗外,CVAP 应在感染发生后立即拔除。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验